International Journal of Biological Sciences · 2024 · 22 citations · 0 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer BiomarkersCancer ImmunotherapyCheckpoint Inhibitor TherapyColorectal CancerImmune Checkpoint InhibitorsImmune CheckpointsCheckpoint Antagonist TherapyImmune Checkpoint Blockade ResistanceImmune Checkpoint Inhibitor BiomarkersImmune Checkpoint Inhibitor TherapyImmune Checkpoint ResistanceResistance To Checkpoint InhibitorsResistance To Immune Checkpoint InhibitionTherapeutic Target Identification
In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.